US FDA's reputation under assault, as public sees it is influenced by politics

4 June 2006

The majority of US adults think that the Food and Drug Administration's most important function is to ensure the safety and efficacy of new prescription drugs, according to the findings of a new Wall Street Journal/Harris Interactive Health-Care poll. This included 2,371 US adults and was conducted between May 12 and 16.

However, over the past two years, the public has become increasingly skeptical about the agency's ability to meet that mission, with seven in 10 adults giving the FDA a negative rating. A vast majority of adults are concerned about the agency's ability to make independent decisions that will ensure public access to safe and effective drugs. In addition, large majorities - across party lines - say the FDA's decisions are influenced by politics rather than medical science. All of this suggests the agency is facing an uphill battle in the court of public opinion, the research conscludes.

According to the poll, most adults say they are concerned about the FDA's ability to make independent decisions that will ensure that patients have access to safe and effective medicines (80%), and its ability to effectively communicate safety concerns about prescription drugs to doctors and the public (76%).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight